trending Market Intelligence /marketintelligence/en/news-insights/trending/2mYRpEFmNNl9gBv_1KMrWw2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Ergomed buys US pharmacovigilance services provider for $10M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Ergomed buys US pharmacovigilance services provider for $10M

London-listed Ergomed PLC said it acquired U.S.-based pharmacovigilance services provider Ashfield Pharmacovigilance Inc. for $10 million.

Ergomed bought Ashfield from UDG Healthcare PLC, and plans to combine it with its PrimeVigilance division, which offers pharmacovigilance services that are meant to detect and prevent adverse effects or any other possible drug-related problems during the development of a medicine.

Ashfield generated $11.6 million in revenues during the financial year ended Sept. 30, 2019, and recorded an adjusted EBITDA of $900,000. The business had net assets of $2.8 million. Ashfield Pharmacovigilance also has a backlog of sales totaling $9.8 million.

Ergomed said it would fund the purchase using existing cash resources and that it expects to acquisition to contribute toward its 2020 earnings.